Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 Genitourinary Cancers Symposium /
Docetaxel with androgen deprivation therapy combo in hormone-naïve metastatic prostate cancer

26th - 28th Feb 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 28.02.15
Views: 3061
Rating:

Dr Gwenaëlle Gravis - Institut Paoli-Calmettes, Marseilles, France

Dr Gwenaëlle Gravis talks to ecancertv at ASCO GU 2015 about the results of the GETUG-AFU 15 phase III trial.

Long-term follow-up results suggest that the addition of docetaxel to androgen deprivation therapy did not significantly improve overall survival in patients with hormone-naïve metastatic prostate cancer.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation